300122 Chongqing Zhifei Biological Products
- 28.33
- +0.42+1.50%
Chongqing Zhifei Biological Products News
Chongqing Zhifei Biological Products: Legal Opinion of King & Wood Mallesons (Chongqing) Law Firm on the 2023 Shareholders' Meeting of Chongqing Zhifei Biological Products Co., Ltd. in Beijing
Chongqing Zhifei Biological Products: Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Chongqing Zhifei Biological Products: Announcement on the approval notice for clinical trials of the 26-valent pneumococcal conjugate vaccine
Zhifei Biotech: Announcement on changing the registered capital and amending the company's articles of association
Zhifei Biotech: Report of the Audit Committee of the Company's Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Zhifei Biotech: Announcement on holding an online briefing on the 2023 annual results
Zhifei Biotech: Announcement on changing the names of employee representatives and supervisors
Zhifei Biotech: Notice on holding the 2023 Annual General Meeting of Shareholders
Zhifei Biotech: 2023 Internal Control Evaluation Report
Zhifei Biotech: 2023 Annual Financial Results Report
Zhifei Biotech: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Zhifei Biotech: Announcement on repurchasing shares to cancel and reduce registered capital and notify creditors
Zhifei Biotech: Legal Opinion of Beijing Jindu (Chongqing) Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Chongqing Zhifei Biological Products Co., Ltd.
Zhifei Biotech: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Zhifei Biotech: Announcement on Action Plans to Promote Double Improvement of Quality and Return
Zhifei Biotech: Announcement on the acceptance of clinical applications for the 26-valent pneumococcal conjugate vaccine
Zhifei Biotech: Announcement on the entry of the component DPT vaccine into phase III clinical trials
Zhifei Biotech: Announcement on the entry of therapeutic BCG into phase I clinical trials
Zhifei Biotech: Announcement of Resolutions of the First Extraordinary General Meeting of Shareholders in 2023
Zhifei Biotech: Legal Opinion of Beijing Jindu (Chongqing) Law Firm on the 2023 First Extraordinary General Meeting of Shareholders of Chongqing Zhifei Biological Products Co., Ltd.
Analysis
Price Target
No Data
